ArticleBMC medicine2022

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.

Qingyuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.